` QNCX (Quince Therapeutics Inc) vs S&P 500 Comparison - Alpha Spread

QNCX
vs
S&P 500

Over the past 12 months, QNCX has significantly outperformed S&P 500, delivering a return of +150% compared to the S&P 500's +13% growth.

Stocks Performance
QNCX vs S&P 500

Loading
QNCX
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
QNCX vs S&P 500

Loading
QNCX
S&P 500
Difference
www.alphaspread.com

Performance By Year
QNCX vs S&P 500

Loading
QNCX
S&P 500
Add Stock

Competitors Performance
Quince Therapeutics Inc vs Peers

S&P 500
QNCX
ABBV
AMGN
GILD
VRTX
Add Stock

Quince Therapeutics Inc
Glance View

Market Cap
83.8m USD
Industry
Biotechnology

Cortexyme, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics. The company is headquartered in South San Francisco, California and currently employs 55 full-time employees. The company went IPO on 2019-05-09. The firm is focused on advancing precision therapeutics targeting debilitating and rare diseases. The firm has discovered a bone-targeting drug platform capable of delivering small molecules, peptides, or large molecules directly to the site of broad bone fractures and disease designed to promote more healing with fewer off-target safety concerns. The Company’s lead compound, NOV004, is an anabolic peptide engineered to target and concentrate at the bone fracture site. Its discovery pipeline is focused on expanding across multiple skeletal therapeutic indications, including osteogenesis imperfecta, fractures, spinal fusion, and other severe diseases of bone such as cancer or infection. The firm's pipeline also includes legacy neuroscience and antiviral programs available for out-licensing, which include COR588, COR388, COR852 and COR803.

QNCX Intrinsic Value
Not Available
Back to Top